Biologic drugs induced vitiligo: case reports and review of literature Authors: Xinyi Shao, Tingqiao Chen, Xingyu Pan, Shuang Chen, Yangmei Chen, Jin Chen Published: 2024 ABSTRACT Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo. This study reports two cases of new-onset vitiligo following dupilumab treatment for AD. The first case involves an 80-year-old male who developed vitiligo patches appeared on the chest, back, and lower limbs after 2 months of dupilumab therapy. Despite discontinuation of dupilumab, the vitiligo did not regress. The second case describes a 14-year-old female who experienced depigmentation on her forehead one month into dupilumab treatment, with partial improvement of vitiligo lesions over time despite continued therapy. This phenomenon may be due to dupilumab blocking type 2 inflammation, disrupting normal skin homeostasis, and exacerbating type 1 inflammation. These cases, supplemented with a literature review, highlight the potential for biologic drug-induced vitiligo and underscore the need for awareness of such adverse events in clinical practice. The mechanisms underlying this phenomenon likely involve disruption of the Th1/Th2/Th17 cytokine balance, suggesting that targeted therapies may inadvertently exacerbate type 1 inflammation, leading to vitiligo. With the rising use of biologics, clinicians should carefully consider the risk of vitiligo when prescribing these treatments. Introduction Biological drugs have become a common treatment for many inflammatory conditions due to their effectiveness and high safety profile (1–3). Atopic dermatitis and vitiligo are chronic, inflammatory skin diseases that can significantly impact the quality of life of those affected (4, 5). Dupilumab, a human interleukin-4 receptor alpha antagonist, inhibits IL-4 and IL-3 signaling (6). It is widely used in patients with moderate to severe atopic dermatitis (AD) who do not respond adequately to conventional therapies. Adverse events such as injection-site reactions, paradoxical erythema, ophthalmic complications, and alopecia areata have drawn the attention of dermatologists (7). However, cases of dupilumab-induced vitiligo in patients with atopic dermatitis are rare in existing literature, and there is a lack of cases in Chinese. Here, we present two instances of new-onset vitiligo in Chinese patients with atopic dermatitis who received dupilumab injections for their condition. Case reports Case 1 In October 2023, an 80-year-old male patient with AD visited our department due to a poor response to repeated antihistamine treatment and a fungal infection following the use of topical steroids. The patient had a history of AD for more than 30 years; however, he reported no personal or family history of vitiligo. A physical examination revealed erythema, papules, and thickened plaques on the trunk and lower limbs, with a Scoring of Atopic Dermatitis (SCORAD] score: 50.5, an Investigator Global Assessment (IGA] score: 5, and a Numeric Pain Rating Scale (NRS of 10). Laboratory tests revealed an increased serum immunoglobulin E (IgE) level (2990 IU/mL; normal: 5-136 IU/mL). Fungal microscopy confirmed a fungal infection in both lower limbs. According to the typical clinical manifestations of the patient and subsequent auxiliary examinations, AD was identified. Given the poor efficacy of conventional therapies and the presence of a fungal infection, the patient was administered dupilumab (600 mg induction dose and then 300 mg every 2 weeks). After 2 months, there was a slight improvement in erythema and papules (SCORAD: 43.6; IGA: 3; NRS: 4) ( Figure 1A ). However, he developed irregular light white patches on the chest, back, and lower limbs with a Vitiligo Area Score Index (VASI) score of 1.175. The patient requested to continue treatment with dupilumab. (A) Irregular light white patches sparing the chest, back, and lower limb area after 2 months of treatment with dupilumab. (B) Further enlargement of white patches on the trunk and lower limbs after 5 months of treatment with dupilumab. (C) Woolamp examination of depigmented patches on the chest, back, and lower limbs showing white fluorescence, confirming the diagnosis of vitiligo. After 5 months of treatment, his erythema and papules essentially vanished (SCORAD: 27.7; IGA: 2; NRS: 2). However, the white patches on his trunk enlarged, and Wood lamp examination revealed bright white patches, indicating that the patient was in the progression stage of vitiligo (VASI: 1.51) ( Figures 1B, C ). It was decided to discontinue dupilumab treatment and use glycyrrhizin. Eight weeks after the cessation of dupilumab, the patches had not reduced in size. Case 2 A 14-year-old female patient presented with moderate to severe atopic dermatitis, which she had experienced since the age of 4. She had no personal or familial history of vitiligo. Despite treatments with antihistamines and topical corticosteroids, the results were unsatisfactory. Physical examination revealed erythema, papules, and thickened plaques in the hands and both upper limbs, with (SCORAD: 48.4; IGA: 5; NRS: 10). Laboratory assay results revealed increased IgE levels. The patient received dupilumab treatment, receiving an initial loading dose of 600 mg, followed by 300 mg every 2 weeks. At the one-month follow-up visit, improvements in the AD skin lesions were observed (SCORAD: 14.6; IGA: 1; NRS: 3). However, a patch of depigmentation appeared on her forehead, accompanied by gray hair (VASI: 0.24). Dermatoscopy and wood lamp examination confirmed the diagnosis of vitiligo ( Figure 2 ). Treatment with topical hydrocortisone butyrate ointment was initiated, and dupilumab therapy was continued at the request of the patient. After five months, partial improvement of the vitiligo lesions was observed. (A) Clinical photographs of a 14-year-old female patient with atopic dermatitis who developed vitiligo after treatment with dupilumab. (B, C) Wood lamp examination and dermatoscopy of the patient. Discussion Here, we present two cases of de novo vitiligo, a Th1 cell-mediated inflammatory skin disease, following dupilumab therapy for AD. Vitiligo is a common mucocutaneous depigmentation disorder caused by cytotoxic CD8+ T cell-mediated destruction of melanocytes (5). Recent studies highlighted significant changes in the expression of inflammatory cytokines in vitiligo lesions (8, 9). Consistent with this, previous reports have documented cases of vitiligo induced by biologic drugs such as anti-IL17 agents and anti-TNF α drugs. Despite only two cases of biological agent-induced vitiligo reported in a nationwide cohort study, this adverse event warrants attention. Published cases of biologic drug-induced vitiligo are summarized in Table 1 (10–38). Thirty-seven cases (26 male patients and 11 female patients) of vitiligo associated with biologic drug use have been reported. Of these cases, 10 were related to adalimumab, nine were related to dupilumab, seven were related to infliximab, five were related to ixekizumab, five were related to secukinumab, and one was related to ustekinumab. Most patients received conventional therapy after developing vitiligo, such as topical steroids, topical tacrolimus and phototherapy. Fourteen patients showed varying degrees of discoloration after treatment, and seven patients showed stable condition of vitiligo after treatment. Notably, six patients chose to continue using biologics, their white patch also improved after treatment. Table 1Literature review of biologic drugs-induced vitiligo.BiologicsYear, authorAge (years)SexBiologic drugs indicationAreas AffectedOnset (months)Biologic drugs withdrawalPrevious history of vitiligoManagementOutcomeDupilumab2021, Takeoka S et al (10)17MADForehead3NoYesHydrocortisone butyrate ointment, delgocitinib ointment, 10 sessions of excimer light therapyAfter 17 months slight repigmentation, its area has not shrunk.2023, Ren H et al (11)18MADBilateral cheeks, neck3YesNoTacrolimus 0.1% ointmentN/A50FADRight hairline, neck, and chest2YesNoMometasone 0.1% ointment and Nb- UVBN/A40FADHands and feet8NoNoNoneN/A50MADHands, legs, and feet1NoNoTriamcinolone acetonide 0.1% ointment and tacrolimus 0.1%N/A18FADPelvis, left leg, and lower torso.6.25NoYesTriamcinolone acetonide 0.1% ointmentN/A43FNPFace, bilateral breasts, chest,abdomen, bilateral forearmsand proximal thighs15NoYesBetamethasone dipropionate 0.05% cream, tacrolimus 0.1% ointment, and Nb- UVB.N/A52MNPForehead, glabella, nose andcheeks2NoYesRuxolitinib 1.5% cream and Nb- UVBN/A2023, Picone V et al (12)79MADScalp, neck, and back of thehands1NoNoTopical corticosteroids and nb-UVBRemissionIxekizumab2023, Su HJ et al72FPsoriasisFace4YesNoExcimer and cyclosporine75% repigmentation of the face after 3 months ofcyclosporine with control of psoriasis2019,Federico Pirro et al (14)48MPsoriasisLegs, hands, feet3NoNoTopical tacrolimus 0.1% ointment for 8 weeks without discontinuation of ixekizumab50% repigmentation at 4 months of follow-up2021, Marasca C et al (15)53MPsoriasisFace3NoNoTopical calcineurin inhibitorsN/A2022, Eker H et al (16)71MPsoriasisCheeks and perioral areas2NoNoTopical corticosteroids and topical pimecrolimusN/A2022, Pathmarajah P et al (17)36MPsoriasisTrunk, limbs, and face11NoNoNoN/ASecukinumab2023, Bouzid S et al (18)30MPsoriasisHands, palms, and back9NoNoTopical steroidsPartial repigmentation2020, Nieto-Benito LM et al (19)39MPsoriasisAxillae, neck, arms, feet24NoNoTopical tacrolimusStability2020, Nieto-Benito LM et al (19)20FPsoriasisAxillary12NoNoTopical tacrolimusStability2023, Kim JC et al (20)38MPsoriasisLegs21NoYesTopical tacrolimusStability2021, Giordano D et al (21)42FPsoriasisUpper limbs and trunk12NoNoN/ARepigmentationAdalimumab2020, Palazzo G (22)63MPsoriasisPalms12YesNoSecukinumabResolution2020, Tirado-Sánchez A et al (23)45MPsoriasisTrunk and hands1YesNoUstekinumabN/A2020, Phan K et al (24)24FHSBack and posterior legs4N/ANoN/AN/A2008, Smith DI et al (25)66MPsoriasisArms and trunk5NoNoN/AStability2011, Posada C et al (26)54FCrohn’s diseaseUpper extremities and trunk8NoNoN/AN/A2024, Değirmenci MFK et al (27)34MIdiopathic UveitisLower jaw area5NoNoTopical tacrolimusStability2021, Yang HJ et al (28)22MHealthy volunteerNeck and chest2YesNoA combination of weekly excimer laser and twice per day application of topical tacrolimusPartly repigmentation2015, Jung JM et al (29)39FCrohn’s diseaseExtremities12NoNoExcimer laser and topical tacrolimusStability2013, Maruthappu T et al (30)57MASFace, hands, and axillae3YesYesTopical clobetasol proprionate ointment and tacrolimus 0.1% ointmentPartial repigmentation2013, Maruthappu T et al (30)30MASTrunk and limbs6NoNoN/AStabilityUstekinumab2020, Gedikli OK et al (31)33MPsAThe dorsum of the fingers4N/ANoN/AN/AInfliximab2014, Carvalho CL et al (32)46FRALeft upper limb and left hemithorax2NoNoTopical 10% phenylalanine, clobetasol 0.025%, 2% vitamin E, and Polipodium leucotomos 240 mg/day orally for 30 days.No improvement2005, Ramírez-Hernández M et al. (33)61MRAThe dorsa of the hands6NoNoOral polypodium leucotomus extracts and topical pseudocatalase cream50% repigmentation2013, Mattox AR et al. (34)60MPityriasis Rubra PilarisThe dorsal fingers and left wrist28YesNoTacrolimus 0.1% ointment twice daily and nb-UVBRepigmentation2017, Ryu TH et al (35)34MUlcerative colitisThe right mandibular and auricular area4N/ANoN/AN/A2019, Lu X et al (36)39MPsoriasisForehead3NoNoN/ARepigmentation2011, Ismail WA et al (37)51MUlcerative colitisFace1YesNoTopical tacrolimus ointment, combined with excimer laserImprovement with the reappearance of pigmentation near the margins2017, Luber RP et al (38)83MCrohn’s diseaseLimbs and trunk8NoNoA combination of compounded tacrolimus 0.1% ointment and calcipotriol–betamethasone dipropionate ointment, both twice dailyModerate improvementAD, atopic dermatitis; AS, ankylosing spondylitis; F, female; HS, hidradenitis suppurativa; M, male; nb-UVB, narrow-band ultraviolet B; NP, nasal polyposis; NS, non-segmental; PsA, psoriatic arthritis; RA, rheumatoid arthritis.N/A, not available. Literature review of biologic drugs-induced vitiligo. AD, atopic dermatitis; AS, ankylosing spondylitis; F, female; HS, hidradenitis suppurativa; M, male; nb-UVB, narrow-band ultraviolet B; NP, nasal polyposis; NS, non-segmental; PsA, psoriatic arthritis; RA, rheumatoid arthritis. N/A, not available. The mechanisms underlying the development of vitiligo during biological therapy remain unknown. Previous studies suggested that blocking the TNF α pathway may have therapeutic potential in treating vitiligo skin lesions. However, some clinical cases have also reported that TNF α inhibitors may be associated with the emergence or progression of vitiligo (23–38). The underlying mechanism of anti-TNF α agents-induced vitiligo may involve local changes in cytokine balance and the activation of alternative pathways such as type I interferon (39). Additionally, TNF α may decrease regulatory T cell (Treg) production and activation and impair Treg skin homing that allows T cells to self-react to melanocytes (40). IL-17 antagonist-induced vitiligo highlights the delicate balance between Th1 and Th17 regulation. The absence of one of these effector cytokines can promote a response dominated by the other. A previous animal study suggested that IL-17 deficiency contributes to increased IFN-γ+Th1 cells and an elevated Th1 response (41). Additionally, because of the association between the onset of vitiligo and genetic variations, some studies suggested that biologics may cause vitiligo by intervening in the innate immunity of specific genetically susceptible patients (42, 43). Vitiligo is related to other immune diseases; therefore, vitiligo development may be coincidental and related to underlying diseases (40). Vitiligo and AD are common chronic autoimmune inflammatory skin diseases. Previous studies indicated that patients with AD are at a higher risk of developing autoimmune diseases such as vitiligo. Conversely, individuals with vitiligo have an elevated incidence of AD compared to those without vitiligo (44, 45). The treatment of vitiligo is more difficult than that of AD; however, the use of ruxolitinib may allow repigmentation after vitiligo (46). Dupilumab is a fully human monoclonal antibody targeting the IL-4 receptor α, inhibiting both IL-4 and IL-13 signaling. Only a few isolated cases of dupilumab-induced vitiligo have been reported. This study contributes to the existing literature by documenting additional cases, specifically highlighting instances of vitiligo induced by dupilumab in Chinese patients. We speculated that this phenomenon occurs due to dupilumab disrupting the balance between helper T cell (Th) 2 and Th1/Th17 pathways. Sushama S et al. suggested that dupilumab-induced IL-4 inhibition leads to Th1/Th17 polarization, resulting in increased expression of IL-17, IL-2, TNF-α, and IFN-γ, which are implicated in the pathogenesis of vitiligo (47). Dupilumab blocks type 2 inflammation, disrupting normal skin homeostasis and potentially exacerbating type 1 inflammation, thereby inducing vitiligo. With the increasing use of biological agents in patients with skin diseases, clinicians should consider the possibility of adverse reactions like vitiligo when selecting targeted biological therapies. However, our study also has some limitations, including a small sample size and the possibility of potential confounding factors. Future clinical studies with larger sample sizes can better clarify the possible mechanisms of biologics induced vitiligo, and future studies could examine if JAK inhibition may be superior in patients.